相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Saint Louis University's Center for Vaccine Development will enroll up to 30 healthy adult volunteers in a Phase 1 clinical trial to evaluate the safety and immune response of an updated investigational West Nile virus vaccine. - The study addresses a critical unmet medical need, as no approved vaccine or treatment currently exists for West Nile virus, which has caused over 28,000 cases of neuroinvasive disease and 2,600 deaths in the U.S. since 1999. - Participants aged 18-49 will receive either the experimental vaccine or placebo across three doses over 13 months, with the trial being the only research site for this Phase 1 study. - The research builds on promising safety data from an earlier vaccine version and is funded by the National Institute of Allergy and Infectious Diseases as part of ongoing efforts to develop effective protection against this mosquito-borne pathogen.
- Two-year follow-up data from enVVeno Medical's VenoValve trial demonstrates 78% of subjects maintained clinically meaningful improvement in venous disease severity scores. - The study showed increasing benefits over time, with average rVCSS improvement rising from 6.6 points at 12 months to 8.2 points at 24 months among responders. - Device maintains 100% patency rate in evaluable subjects at 24 months, while patients experienced 75% reduction in pain and sustained quality of life improvements.
